Home | Welcome to Contract Pharma   
Last Updated Monday, July 28 2014
Print RSS Feed

Financial Report: Johnson & Johnson



Published January 22, 2013
Johnson & Johnson
 
4Q Revenues: $17.6 billion (+8%)

4Q Earnings: $2.6 billion (earnings were $218 million in 4Q12)

YTD Revenues: $67.2 billion (+3%)

YTD Earnings: $10.5 billion (+9%)

Comments: Pharmaceutical sales were $6.5 billion in the quarter, up 7%, and $25.4 billion for the year, up 4%. Remicade sales were $1.5 billion in the quarter, up 5% and $6.1 billion for the year, up 12%. Simponi sales were up 52% to $181 million in the quarter, and up 48% to $607 million for the year. Stelara sales were $269 million in the quarter, up 30%, and $1.0 billion for the year, up 39%. Risperdal Consta sales were down 7% to $358 million in the quarter, and down 10% for the year to $1.4 billion. Velcade sales were up 43% in the quarter and 18% for the year to $502 million and $1.5 billion, respectively. Consumer sales were flat at $3.7 billion in the quarter, and up 3% for the year, to $14.4 billion. Medical Devices and Diagnostics revenue was $7.4 billion in the quarter, up 14%, and $27.4 billion for the year, up 6%. 2012 results included $4.2 billion charges for product liability expenses, litigation, and costs associated with the DePuy Hip recall.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On